PolyPid Files NDA for D-PLEX100 to Prevent Colorectal Surgery Infections

A 60% statistically significant reduction in incisional surgical site infections, demonstrated across 798 patients with large abdominal surgery incisions in the Phase 3 SHIELD II trial, is the clinical foundation behind PolyPid Ltd.'s formal move toward FDA approval. The Nasdaq-listed biopharmaceutical company initiated a New Drug Application submission for D-PLEX100, its lead candidate for preventing surgical site infections in colorectal surgery, filing the first modules with the U.S. Food and Drug Administration on March 31.

The filing targets a problem that carries enormous weight inside hospital budgets. Surgical site infections account for an estimated $3.2 billion in attributable costs per year to acute care hospital budgets in the United States. Colorectal procedures carry a disproportionate share of that burden: SSI rates in colorectal surgery are significantly higher than those of similar operative sites, and the per-patient financial consequences can be severe. Adjusted increased costs associated with infections range from $36,429 to $144,809 for commercial payers and from $17,551 to $102,280 for Medicare, depending on the type of surgical site infection.

D-PLEX100 is designed to address the problem at the source. The product relies on PolyPid's PLEX polymer-lipid encapsulation technology, which pairs with the broad-spectrum antibiotic doxycycline to enable a prolonged, continuous local release, maintaining high drug concentrations at the surgical site for 30 days after the incision is closed. That sustained-release mechanism also carries implications for antibiotic-resistant bacteria, since high local concentrations can act against resistant organisms that systemic prophylaxis may not adequately reach.

The submission structure matters for understanding the timeline. PolyPid is filing under a rolling NDA review, a mechanism available to drugs with FDA Fast Track designation that allows a company to submit completed modules sequentially rather than delivering a single complete package at once. The FDA agreed to the rolling review arrangement, allowing PolyPid to submit the first completed sections in early 2026. The Chemistry, Manufacturing and Controls and nonclinical modules have already been filed; the clinical module and remaining components are expected in the second quarter of 2026. PolyPid has also secured a PDUFA fee waiver, reducing the regulatory cost burden that typically accompanies a domestic NDA submission.

The SHIELD II trial also successfully met all key secondary efficacy endpoints, including a 58% reduction in the rate of surgical site infections. CEO Dikla Czaczkes Akselbrad called the NDA initiation "a pivotal milestone," framing the filing as a step toward potential approval and commercialization in the U.S. market. The company is simultaneously conducting commercialization partnership negotiations with U.S. distributors, standard practice for an Israel-based biotech seeking to access a hospital procurement ecosystem that requires established commercial infrastructure.

For hospital pharmacy and surgery teams evaluating D-PLEX100, the questions that will follow any eventual approval center on workflow integration, formulary placement, and payer coverage. Local prophylactics applied at the surgical site add a procedural step, and adoption will hinge on whether the infection-reduction data translates into net cost savings that justify reimbursement at prices hospitals can accept. The comparative effectiveness question, specifically how D-PLEX100 performs against enhanced standard prophylaxis protocols already in use at high-volume colorectal centers, will likely factor into payer negotiations and guideline considerations.

With the clinical module due before mid-year, the completeness of the NDA submission will be the next critical marker on the path toward a potential approval decision.